Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03

Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet (2013) 4.71

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet (2014) 4.59

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet (2013) 3.40

Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA (1996) 3.14

Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol (2008) 2.98

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47

IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 2.24

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology (2014) 1.70

Significance of elevated cobalamin (vitamin B12) levels in blood. Clin Biochem (2003) 1.61

Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology (1997) 1.49

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48

Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut (2012) 1.43

Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol (2010) 1.04

High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study. Digestion (2012) 1.03

Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int (2012) 0.98

Replication of the hepatitis C virus. Baillieres Best Pract Res Clin Gastroenterol (2000) 0.95

Vitamin B12 and hepatitis C: molecular biology and human pathology. Proc Natl Acad Sci U S A (2001) 0.92

Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. J Med Virol (2012) 0.84

Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection. J Med Virol (2013) 0.83

THE VITAMIN B12 CONTENT OF HUMAN LIVER TISSUE OBTAINED BY ASPIRATION BIOPSY. Gut (1963) 0.81

Vitamin B12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site. J Mol Biol (2002) 0.80

Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection. J Viral Hepat (2011) 0.80

Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection. J Med Virol (1999) 0.80

Differential effects on the hepatitis C virus (HCV) internal ribosome entry site by vitamin B12 and the HCV core protein. J Virol (2004) 0.79

Vitamin B(12) and folic acid imbalance modifies NK cytotoxicity, lymphocytes B and lymphoprolipheration in aged rats. Nutrients (2013) 0.79